Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014;10(10):2992-3.
doi: 10.4161/21645515.2014.971643.

Hepatitis B vaccine adverse events in China: risk control and regulation

Li Meina  1 , Liu Xiaodong, Zhang Lulu
Affiliations

Hepatitis B vaccine adverse events in China: risk control and regulation

Li Meina et al. Hum Vaccin Immunother. 2014.

Abstract

The death of 17 children raised public fears over infant hepatitis B vaccination in China. Though the relation between hepatitis B and children's death was denied after prudent investigation, the negative impact remained. In order to prevent or minimize adverse events after vaccination, special strategy including regulation and reimbursement should be developed.

Keywords: adverse events following immunization; hepatitis B vaccine; post-baccination; regulatory science; vaccine safety.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Kang W, Ding Z, Shen L, Zhao Z, Huang G, Zhang J, Xiong Q, Zhang S, Zhang S, Wang F. Risk factors associated with immunoprophylaxis failure against mother to child transmission of hepatitis B virus and hepatitis B vaccination status in yunnan province, China. Vaccine 2014; 32:3362 -6; PMID:24793939; http://dx.doi.org/10.1016/j.vaccine.2014.04.045 - DOI - PubMed
    1. Ko SC, Schillie SF, Walker T, Veselsky SL, Nelson NP, Lazaroff J, Crowley S, Dusek C, Loggins K, Onye K, et al. Hepatitis B vaccine response among infants born to hepatitis B surface antigen-positive women. Vaccine 2014; 32:2127-33; PMID:24560676; http://dx.doi.org/10.1016/j.vaccine.2014.01.099 - DOI - PubMed
    1. Eng NF, Bhardwaj N, Mulligan R, Diaz-Mitoma F. The potential of 1018 ISS adjuvant in hepatitis B vaccines HEPLISAV (TM) review. Hum Vaccin Immunother 2013; 9:1661-72; PMID:23732907; http://dx.doi.org/10.4161/hv.24715 - DOI - PMC - PubMed
    1. Stuebgen J-P. Immune-mediated myelitis following hepatitis B vaccination. Autoimmun Rev 2012; 12:144-9; PMID:22498789; http://dx.doi.org/10.1016/j.autrev.2012.03.008 - DOI - PubMed
    1. Martinez-Sernandez V, Figueiras A. Central nervous system demyelinating diseases and recombinant hepatitis B vaccination: a critical systematic review of scientific production. J Neurol 2013; 260:1951-9; PMID:23086181; http://dx.doi.org/10.1007/s00415-012-6716-y - DOI - PubMed

Publication types

Substances

LinkOut - more resources